UBS Keeps Its Buy Rating on Boston Scientific

Analyst David Lothson says stent sales topped estimates, boosting confidence in his earnings forecasts

UBS Financial reiterated its buy rating on Boston Scientific (BSX ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.